Financial Data and Key Metrics Changes - The first quarter of 2020 revenue was $230 million, up 13% compared to the first quarter of 2019, primarily due to increased XT Series implementations and annual service revenue from a larger installed base [28] - GAAP earnings per share for the first quarter was $0.26, up from $0.08 in the same period last year, largely due to lower income tax expenses [32] - Non-GAAP EPS for the first quarter was $0.66, compared to $0.61 in the same period last year, representing an 8% year-over-year increase [35] - Cash balance as of March 31, 2020, was $104 million, down from $127 million at the end of 2019, with the company now debt-free [36][40] Business Line Data and Key Metrics Changes - Approximately 24% of the existing installed base of previous generations for automated dispensing cabinets have booked orders to upgrade to the new XT Series, down from 30% at the same time last year [29] - The company experienced minimal impact on revenue and profit from COVID-19 in Q1, but bookings for new sales began to slow in the second half of March [22][31] Market Data and Key Metrics Changes - Health systems are facing increased costs due to COVID-19, leading to decreased revenue from postponed elective surgeries and cash flow challenges [23] - The company has not experienced significant disruption in its supply chain and has maintained appropriate inventory levels to meet customer demand [21] Company Strategy and Development Direction - The company remains committed to its long-term strategy of delivering automation, intelligence, and services to transform the pharmacy-care delivery model [11] - The company believes that COVID-19 has made its solutions more relevant, particularly in managing medication supply chains and supporting healthcare systems during the pandemic [12][24] Management's Comments on Operating Environment and Future Outlook - The company anticipates that COVID-19 demand disruptions will negatively impact 2020 results compared to prior guidance, and it cannot provide meaningful near to medium-term direction at this time [24][43] - The company has a healthy backlog and a strong customer base, with approximately 40% of its business being recurring revenue, which is expected to remain stable during the pandemic [25][26] Other Important Information - The company has implemented various cost-saving measures to preserve liquidity, including the elimination of non-essential travel and hiring delays [42] - The company incurred approximately $1.5 million in additional costs related to airfreight due to COVID-19 [72] Q&A Session Summary Question: Where do you stand on the five-year targets issued in December? - The company believes the long-term strategy remains unchanged and the long-term drivers are still valid [47] Question: Will you be able to implement more resources to drive implementations faster post-recovery? - The company can ramp up resources to meet demands, but implementation timelines will vary by location due to differing COVID-19 impacts [49] Question: Was there a rush to complete implementations at the end of the quarter? - Implementation activity was provider-dependent, with some wanting to expedite while others delayed due to the pandemic [51] Question: How has the relaxation of stay-at-home orders affected access for implementations? - Access remains cautious, with hospitals still limiting outside personnel despite some reopening for elective surgeries [53] Question: Do you expect booking activity to recover sooner than implementations? - It is difficult to predict, as hospital personnel necessary for implementations are still not fully back on-site [55] Question: Have operational changes during the crisis led to any lasting improvements? - The company has accelerated virtual installations and training, which may improve customer experience moving forward [63][68]

Omnicell, Inc. (NASDAQ:OMCL) Q4 2019 Earnings Conference Call February 6, 2020 4:30 AM ET Company Participants Peter Kuipers - CFO Randall Lipps - Founder, Chairman, President & CEO Conference Call Participants Lucas Baranowski - Craig-Hallum Capital Steve Halper - Cantor Gene Mannheimer - Dougherty & Co Jessica Tassan - Piper Bill Sutherland - Benchmark Mitra Ramgopal - Sidoti Operator Thank you for standing by, and welcome to the Omnicell Fourth Quarter 2019 Earnings Announcement. At this time all partici ...

. . . . . . . . . . !! DAMOT OLD DE O : ● . Omnicell Inc. 38th Annual J.P. Morgan Healthcare Conference San Francisco, CA January 15, 2020 . D = DID 10 = U D .. . . . . . . . . . . . . Safe Harbor Statement | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------- ...

Omnicell, Inc. – Investor Presentation October 2019 Omnicell The Autonomous Rx Company 2019 Omnicell, Inc. Content is confidential and proprietary QQO Safe Harbor Statement This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Omnicell, Inc. (or "Omnicell" or "the Company") as of the date of this presentation and are naturally subject to uncertainty and changes in circumstances. Given these uncertainties, you ...

Omnicell, Inc. (NASDAQ:OMCL) Q3 2019 Earnings Conference Call October 24, 2019 4:30 PM ET Company Participants Peter Kuipers - EVP & CFO Randall Lipps - Founder, Executive Chairman, President & CEO Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Michael Ott - Oppenheimer William Sutherland - The Benchmark Company Lalishwar Ramgopal - Sidoti & Company Eugene Mannheimer - Dougherty & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to the Omnicell Third Qu ...

= + LWV ht E Omnicell, Inc. – Investor Presentation July 2019 The Autonomous Rx Company © 2019 Omnicell, Inc. Content is confidential and proprietary + re >( ) ( ) H > ) { } ( ) = Safe Harbor Statement This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Omnicell, Inc. (or "Omnicell" or "the Company") as of the date of this presentation and are naturally subject to uncertainty and changes in circumstances. G ...